CannaPharmaRX Statistics
Total Valuation
CannaPharmaRX has a market cap or net worth of 2.89 million. The enterprise value is 17.58 million.
| Market Cap | 2.89M |
| Enterprise Value | 17.58M |
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CannaPharmaRX has 656.27 million shares outstanding. The number of shares has increased by 102.40% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 656.27M |
| Shares Change (YoY) | +102.40% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 3.66% |
| Owned by Institutions (%) | n/a |
| Float | 607.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.52 |
| PB Ratio | -0.15 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.77 |
| EV / Sales | 21.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.04
| Current Ratio | 0.04 |
| Quick Ratio | 0.00 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.59 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -19.96% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 24.17% |
| Revenue Per Employee | 31,544 |
| Profits Per Employee | -380,992 |
| Employee Count | 26 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 3.55 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.00% in the last 52 weeks. The beta is -1,525.90, so CannaPharmaRX's price volatility has been lower than the market average.
| Beta (5Y) | -1,525.90 |
| 52-Week Price Change | -56.00% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 40.71 |
| Average Volume (20 Days) | 38,561 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, CannaPharmaRX had revenue of 820,137 and -9.91 million in losses. Loss per share was -0.02.
| Revenue | 820,137 |
| Gross Profit | -2.96M |
| Operating Income | -3.61M |
| Pretax Income | -9.91M |
| Net Income | -9.91M |
| EBITDA | -3.48M |
| EBIT | -3.61M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 2,156 in cash and 14.06 million in debt, giving a net cash position of -14.06 million or -0.02 per share.
| Cash & Cash Equivalents | 2,156 |
| Total Debt | 14.06M |
| Net Cash | -14.06M |
| Net Cash Per Share | -0.02 |
| Equity (Book Value) | -19.81M |
| Book Value Per Share | -0.03 |
| Working Capital | -24.73M |
Cash Flow
| Operating Cash Flow | -1.70M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -439.59% |
| Pretax Margin | -1,207.82% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CannaPharmaRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -102.40% |
| Shareholder Yield | -102.40% |
| Earnings Yield | -343.05% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CannaPharmaRX has an Altman Z-Score of -16.72. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.72 |
| Piotroski F-Score | n/a |